AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

AbbVie Inc. (NYSE:ABBV) is one of the best low risk stocks to buy in 2026. On May 5, AbbVie presented 18 abstracts at the ...

AbbVie Inc. (NYSE:ABBV) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on AbbVie (NYSE: ABBV), buoyed by the company’s inflammatory ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Shares of AbbVie Inc. ABBV advanced 1.04% to $214.50 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.17% to 7,445.72 ...

On May 15, Evercore ISI slightly trimmed its price target on AbbVie Inc. (NYSE:ABBV) from $236 to $235, but maintained its ...

BeiGene Ltd. failed to convince a federal judge to dismiss AbbVie Inc.'s lawsuit accusing the biotechnology company of hiring ...

AbbVie Inc. (NYSE:ABBV) on Monday shared topline results from the Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) compared to placebo for upper limb essential tremor. Upper limb essential ...

NYSE:ABBV Earnings and Revenue History May 15th 2026 A Closer Look At AbbVie's Earnings. As finance nerds would already know, ...

AbbVie Inc. agreed to buy an experimental depression treatment from Gilgamesh Pharmaceuticals Inc. for up to $1.2 billion in a deal that highlights the drug industry’s growing interest in ...